Review of adherence to medications for the treatment of osteoporosis

被引：36
作者：
Gold D.T. [1 ]
Silverman S. [1 ]
机构：
[1] Department of Psychiatry, Center for Aging, Duke University Medical Center, Durham
来源：
Current Osteoporosis Reports | 2006年 / 4卷 / 1期
关键词：
Bone Mineral Density; Osteoporosis; Alendronate; Raloxifene; Risedronate;
D O I：
10.1007/s11914-006-0011-8
中图分类号：
学科分类号：
摘要：
One of the major challenges of successful osteoporosis management is poor patient adherence to current therapies. Individuals who are nonadherent have significant consequences of reduced bone mineral density response, reduced bone marker suppression, and increased risk for fracture compared with individuals who are adherent. Although reducing the dosing interval from daily to weekly oral bisphosphonates has improved adherence, adherence with weekly bisphosphonates remains suboptimal. Barriers to adherence include patient health beliefs, inadequate patient education and age. Potential solutions include increased health care provider-patient interaction, and longer times between doses of medications. Copyright © 2006 by Current Science Inc.
引用
收藏
页码：21 / 27
页数：6
相关论文
共 29 条
  • [1] Sclar D.A., Chin A., Skaer T.L., Et al., Effect of health education in promoting prescription refill compliance among patients with hypertension, Clin Ther, 13, pp. 489-495, (1991)
  • [2] Cramer J.A., Amonkar M.M., Hebborn A., Altman R., Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis, Curr Med Res Opin, 21, pp. 1453-1460, (2005)
  • [3] Sikka R., Xia F., Aubert R.E., Estimating medication persistency using administrative claims data, Am J Manag Care, 11, pp. 449-457, (2005)
  • [4] Dezii C.M., Persistence with drug therapy: A practical approach using administrative claims data, Manag Care, 10, pp. 42-45, (2001)
  • [5] Hart J.T., Commentary: Can health outputs of routine practice approach those of clinical trials?, Int J Epidemiol, 30, pp. 1263-1267, (2001)
  • [6] Osterberg L., Blaschke T., Adherence to medication, N Engl J Med, 353, pp. 487-497, (2005)
  • [7] Claxton A.J., Cramer J., Pierce C., A systematic review of the associations between dose regimens and medication compliance, Clin Ther, 23, pp. 1296-1310, (2001)
  • [8] Berg J.S., Dischler J., Wagner D.J., Et al., Medication compliance: A healthcare problem, Ann Pharmacother, 27, SUPPL. 9, (1993)
  • [9] Miller N.H., Compliance with treatment regimens in chronic asymptomatic diseases, Am J Med, 102, pp. 43-49, (1997)
  • [10] Tosteson A.N., Grove M.R., Hammond C.S., Et al., Early discontinuation of treatment for osteoporosis, Am J Med, 115, pp. 209-216, (2003)
123